pathiostherapeutics.com Open in urlscan Pro
151.101.66.159  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Menu
 * About Us
 * Science
 * Our Team
 * The Board
 * Investors
 * News
 * Contact Us
   
   




PIONEERING A NOVEL MACROPHAGE CONDITIONING APPROACH TO DELIVER BREAKTHROUGH
CANCER THERAPIES


PATHIOS THERAPEUTICS IS AN EARLY-STAGE DRUG DISCOVERY COMPANY TARGETING A
GENETICALLY-VALIDATED INNATE IMMUNE CHECKPOINT AS AN APPROACH TO UNLEASHING THE
POWER OF MACROPHAGES IN THE FIGHT AGAINST CANCER

Find out more



AT PATHIOS WE ARE LEVERAGING A PROPRIETARY KNOWLEDGE OF MACROPHAGE BIOLOGY AND
INNATE IMMUNE CHECKPOINTS BASED ON HUMAN GENETICS, SINGLE CELL TRANSCRIPTOMICS
AND FUNCTIONAL CELLULAR IMMUNOLOGY TO DELIVER FIRST-IN-CLASS AND BEST-IN-CLASS
THERAPIES FOR ADVANCED CANCERS



Science


PIONEERING MACROPHAGE CONDITIONING TO UNLOCK THE POWER OF THE INNATE IMMUNE
SYSTEM AGAINST CANCER

The acidic tumour microenvironment inherent to many cancers causes a profound
immunosuppression of infiltrating immune cells. This disarms the anti-cancer
immune response and negates the effectiveness of current immunotherapies. This
is particularly evident in tumour associated macrophages (TAMs), where acidity
is sensed by the cell-surface receptor, GPR65, leading to an induction of the
transcriptional repressor, ICER (inducible cAMP early repressor), and the
widespread suppression of pro-inflammatory mediators such as TNFα, IL-6 and
IL-12. Pathios is developing drugs to block GPR65 and prevent this signalling,
thereby conditioning macrophages toward a pro-inflammatory, immune-stimulating
phenotype that can reignite an effective anti-tumour immune response and harness
the power of the innate immune system against cancer.






NEWS



April 12, 2022

PATHIOS THERAPEUTICS HIGHLIGHTS ROLE OF GPR65 AS CRITICAL INNATE IMMUNE
CHECKPOINT IN THE HUMAN TUMOR MICROENVIRONMENT AND REPORTS ANTI-TUMOR ACTIVITY
OF GPR65 INHIBITION DURING PODIUM PRESENTATION AT AACR 2022


Read Article

 

July 8, 2021

PATHIOS THERAPEUTICS PRESENTS PRECLINICAL IN VIVO PROOF OF CONCEPT DATA FOR
SMALL MOLECULE GPR65 INHIBITOR IN HUMAN PDX CANCER MODEL


Read Article




LEARN MORE ABOUT PATHIOS AND OUR PURSUIT OF GROUNDBREAKING THERAPIES.



PATHIOS IS BASED IN OXFORD, UK AND BRINGS TOGETHER A TEAM OF EXPERIENCED
SCIENTIFIC LEADERS TO DELIVER NEW THERAPIES IN AUTOIMMUNE DISEASES AND CANCER.
READ ABOUT RECENT DEVELOPMENTS HERE.





PATHIOS' AACR 2022 PRESENTATION



Inhibition of GPR65 counteracts low pH induced immunosuppressive polarization of
macrophages: In vitro and in vivo characterization of potent, selective and
orally bioavailable small molecule GPR65 antagonists.



Download


 * About Us
 * Science
 * Our Team
 * The Board
 * Investors
 * News
 * Contact Us

 * LinkedIn



 * Cookie Policy
 * Privacy Policy


 * © Copyright 2022 | Pathios Therapeutics Ltd | Registered in England & Wales |
   Company No. 10641754

We use cookies to give you the best experience of our site and for us to
understand how our site is used. Click on “I accept” below if you are happy for
us to use cookies. Click on “I do not accept” below if you would like to browse
the site without cookies, other than those that are strictly necessary to make
our site work.
Reject AllAccept All
 
For more detailed information about the cookies we use and how to change or
disable them see our Read More.
Manage consent
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these, the cookies that are categorized as necessary are
stored on your browser as they are essential for the working of basic
functionalities of the ...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
These cookies ensure basic functionalities and security features of the website,
anonymously.

CookieDurationDescriptioncookielawinfo-checkbox-analytics11 monthsThis cookie is
set by GDPR Cookie Consent plugin. The cookie is used to store the user consent
for the cookies in the category "Analytics".cookielawinfo-checkbox-functional11
monthsThe cookie is set by GDPR cookie consent to record the user consent for
the cookies in the category "Functional".cookielawinfo-checkbox-necessary11
monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to
store the user consent for the cookies in the category
"Necessary".cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR
Cookie Consent plugin. The cookie is used to store the user consent for the
cookies in the category "Other.cookielawinfo-checkbox-performance11 monthsThis
cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the
user consent for the cookies in the category
"Performance".viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie
Consent plugin and is used to store whether or not user has consented to the use
of cookies. It does not store any personal data.

Functional
Functional
Functional cookies help to perform certain functionalities like sharing the
content of the website on social media platforms, collect feedbacks, and other
third-party features.
Performance
Performance
Performance cookies are used to understand and analyze the key performance
indexes of the website which helps in delivering a better user experience for
the visitors.
Analytics
Analytics
Analytical cookies are used to understand how visitors interact with the
website. These cookies help provide information on metrics the number of
visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and
marketing campaigns. These cookies track visitors across websites and collect
information to provide customized ads.
Others
Others
Other uncategorized cookies are those that are being analyzed and have not been
classified into a category as yet.
SAVE & ACCEPT